News

Paragonix Technologies, Inc., Announces First Successful Use of Paragonix SherpaPak™ Cardiac Transport System in Pediatric Transplant Recipients

Paragonix Technologies, Inc. today announced that the first series of pediatric donor hearts preserved and transported using Paragonix SherpaPak Cardiac Transport System occurred at University of Florida Health (UF Health) and Le Bonheur Children’s Hospital (TN). Starting in Q1 2019, Paragonix SherpaPak™ CTS have been shipped with heart connectors covering most aortic diameters, permitting the anchoring of variously sized hearts, including small pediatric hearts, to its proprietary suspension system for improved donor heart transport.

Paragonix Technologies, Inc. Announces FDA Clearance and U.S. Launch of the Paragonix SherpaPak™ Pancreas Transport System

Paragonix Technologies, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Paragonix SherpaPak™ Pancreas Transport System (PTS). Starting immediately, the Paragonix SherpaPak™ PTS will be commercially available to pancreas transplant centers and Organ Procurement Organizations. The Paragonix SherpaPak PTS provides unprecedented thermal and physical protection to the donor pancreas during transport from donor to recipient patients.

Paragonix Technologies Cares Program

Paragonix Technologies is happy to announce that we will be sponsoring pet therapy at the University of Florida! Pet therapy can go a long way

Paragonix SherpaPak™ Cardiac Transport System to be Featured in Clinical Presentation at 2019 American Transplant Congress

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. today announced that the Paragonix SherpaPak™ Cardiac Transport System (CTS), the industry’s only FDA cleared and CE marked system for donor organ heart transport and storage, will be featured in a clinical presentation at the 2019 American Transplant Congress. The meeting is being held June 1-5, 2019 in Boston.